Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...
CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer
CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...
CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...
Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC
Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...
Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply
China Isotope & Radiation Corporation (HKG: 1763) announced today that it has signed a Memorandum...
Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares
Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...
Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer
Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...
Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund...
Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...
Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer
Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...
Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC
Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...
Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros
Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license...
Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers
Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...
Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies
Shenzhen Pregene Biopharma Co., Ltd. has entered into a License and Collaboration Agreement with Kite,...
Aosaikang’s AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment
Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced on October 17, 2025, that its subsidiary, AskGene...
Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...
Huadong Medicine Secures NMPA Approval for Relmapirazin Injection, Complementing MediBeacon TGFR Device
Huadong Medicine (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide
Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...
Sinclair’s MaiLi Precise Receives NMPA Acceptance Notice for Class III Device
Sinclair (Hangzhou) Medical Technology Co., Ltd., a wholly‑owned subsidiary of Huadong Medicine (SHE: 000963), announced...